Ignite Creation Date:
2025-12-25 @ 12:21 AM
Ignite Modification Date:
2026-01-10 @ 6:33 PM
Study NCT ID:
NCT03089658
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2019-10-09
First Post:
2017-03-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2017-03-20
First Submit QC Date:
None
Study First Post Date:
2017-03-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-10-07
Last Update Post Date:
2019-10-09
Last Update Post Date Type:
ACTUAL